| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.075 | 0.008 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.009 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.009 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.084 | 0.009 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.21 | 0.009 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.009 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.009 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.082 | 0.009 |